Event overview
Breast Geneity 2025 took place on October 3–4, 2025, at the Mercure Kyiv Congress Hotel, 6 Vadym Hetman Street, Kyiv. The two-day conference gathered breast surgeons, plastic and reconstructive surgeons, clinical oncologists, radiologists, radiation oncologists, rehabilitation specialists, and allied professionals.
The scientific program was curated by a faculty of Ukrainian clinicians, including Dr. Ivan Smolanka and Dr. Olena Martyniuk of the National Cancer Institute of Ukraine. The event is part of the recurring “Geneity” multidisciplinary series hosted at the same venue in recent years.
Clinical and scientific program
Sessions covered management of early and metastatic breast cancer, surgical decision-making, oncoplastic techniques, immediate and delayed reconstruction, radiation considerations after implants, genetics and fertility, and interactive case voting.
Dedicated blocks addressed HER2-positive disease, benign breast conditions, and standards of care. The agenda spanned Surgery and Oncology halls across both days, with faculty-moderated discussions and live clinical polling.
Speakers and institutions
The faculty included leading Ukrainian experts such as :
- Dr. Ivan Smolanka, breast surgeon and senior researcher at the National Cancer Institute of Ukraine (Kyiv);
- Prof. Tetyana Tatarchuk, Deputy Director for Research at the State Institution “O.M. Lukyanova Institute of Pediatrics, Obstetrics and Gynecology of the National Academy of Medical Sciences of Ukraine” (Kyiv); and
- Prof. Serhiy Halych, Head of Microsurgical, Plastic and Reconstructive Surgery, State Institution “A.A. Shalimov National Institute of Surgery and Transplantology” (Kyiv).
Additional sessions featured clinicians including Andrii Liashenko, Oksana Chorna, Anton Loboda, Yuliia Severyn, and Yevhen Probontchuk.
Delta Medical at Breast Geneity 2025
Delta Medical partnered with the conference and engaged clinicians throughout both days. Our Ukraine-wide Key Account Management team staffed the booth and met hospital specialists from multiple regions.
Discussions focused on bone health and skeletal event prevention in oncology, highlighting Xgeva (denosumab, Amgen) for prevention of skeletal-related events in patients with bone metastases and Prolia (denosumab, Amgen) for osteoporosis management in high-risk women on endocrine therapy.
Delta Medical also presented Priora clinical nutrition, including an on-site tasting of the new beet flavor to support tolerance and adherence during therapy. A refreshed visual theme for Xgeva drew strong attention, and team members offered roses at the stand as a simple gesture of appreciation for attendees.
Throughout the breaks, an interactive scientific lottery co-hosted with SCHONEN kept traffic high and created additional touchpoints for medical dialogue.
Across the two days we held targeted meetings with oncology departments from Kyiv and regional centers, agreed post-event medical-education visits, and initiated follow-ups on real-world data needs in bone health and nutrition support.
Materials shared included clinical summaries, dosing and safety cards, and referral pathways for osteoporosis screening aligned to local practice.
Market and practice insights
Content emphasized integrated care: surgical planning linked to adjuvant pathways, reconstruction choices under radiation constraints, and genetics-driven decisions. Recurrent themes relevant to Ukraine and CIS/EAEU markets included expanding access to modern oncoplastic techniques, building local capacity for molecular testing, and improving osteoporosis prevention for women receiving aromatase inhibitors.
These trends match our field experience and reinforce the importance of bone-modifying agents, fracture-risk assessment, and nutrition support within multidisciplinary breast cancer care.
About Delta Medical
Delta Medical is a Swiss pharmaceutical company specializing in the marketing and distribution of prescription medicines, medical devices, and clinical nutrition. We operate across Ukraine, CIS, and EAEU territories with core strengths in regulatory affairs, market access, medical affairs, and tender management. Our teams support partners in oncology, hematology, endocrinology, gastroenterology, dermatology, ophthalmology, and more. To explore commercialization partnerships, visit deltaswiss.eu.
